US Market News
3月前
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing PlatformMarch 4, 2026 10:09 AM
PR Newswire (US)
REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to deliver meaningful quantities of RNA material beyond early research volumes and establishes a potential pathway to further scale-up and manufacturing, subject to program advancement.ECO Synthesis is Codexis' proprietary technology is designed to enable efficient, scalable and high-fidelity production of complex siRNA therapeutics. As RNA therapeutics move beyond rare diseases into larger therapeutic indications, manufacturing demands increase significantly. Codexis believes its ECO Synthesis platform will address these evolving requirements by enabling efficient scale-up while maintaining product consistency. "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," said Alison Moore, President and Chief Executive Officer of Codexis. "Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications."About Codexis, Inc.Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve real-world challenges associated with nucleic acid synthesis and small molecule pharmaceuticals manufacturing. The Company is currently employing its proprietary ECO Synthesis Manufacturing Platform to enable scaled manufacturing of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit codexis.com.
View original content:https://www.prnewswire.co.uk/news-releases/codexis-signs-agreement-to-manufacture-50-g-sirna-using-its-eco-synthesis-manufacturing-platform-302704059.html
Original: Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
TechandBio
1年前
Eli Lilly and Codexis have a collaboration focused on RNA ligase technology, specifically for developing RNAi therapeutics using Codexis's ECO Synthesis™ manufacturing platform.
Collaboration Focus:
Eli Lilly and Codexis are working together to leverage Codexis's enzymatic synthesis technology, including its ECO Synthesis platform, for the development of RNAi therapeutics.
Codexis's Role:
Codexis is a leading enzyme engineering company that uses its proprietary technology to develop and enhance enzymes, including ligases, for various applications, including nucleic acid synthesis.
RNAi Therapeutics:
RNA interference (RNAi) is a biological process that can silence specific genes, making it a promising area for developing new therapies.
ECO Synthesis Platform:
Codexis's ECO Synthesis platform is designed to enable the scaled manufacture of RNAi therapeutics through an enzymatic route, which offers advantages over traditional chemical methods, such as improved product quality and reduced chemical waste.
Ligation:
Ligases are enzymes that catalyze the joining of DNA or RNA strands, a key step in nucleic acid synthesis and RNAi therapeutic development.
Examples of Collaboration:
Codexis has presented data on the enzymatic synthesis of siRNA oligonucleotides using its ECO Synthesis platform, including the enzymatic incorporation of a tissue-targeting moiety.
Codexis has also demonstrated the use of enzymatic ligation to produce siRNA therapeutic assets, combining oligonucleotide fragments made by sequential enzymatic synthesis and traditional phosphoramidite chemistry.
Benefits of Enzymatic Synthesis:
Codexis's ECO Synthesis platform offers several advantages over traditional chemical methods, including:
Improved product quality.
Reduced chemical waste production.
Milder, aqueous reaction conditions.
Higher yields and efficiency.
The Ceo DILLY does Exits at Sierra Oncology and Aimmune therapeutics 1.9 and 2.6 Billion. CDXS will be bigger than the two combined.
This is a technology company that makes next generation drugs in a aquas based more important now with Tariffs in place RFK will back an enzymatic solution for drug manufacturing no more solvents and toxins from china India & Mexico very imperative now with Tariffs in place CDXS is the world wide leader in Enzymatic Solutions (water based environment) RNAI will be the biggest growing modality of drugs 2x a year dosing for large & small indications.Today companies like Agilent use 7000 kilos of waste and toxins to make a few kilos RNAI today. Partnership announcement with LLY OR ALNY or a big player launches the price. Smart $ keeps adding as retail with no patience and adolescent emotional low IQ are selling their shares I remember when PLSE was trading at the same price years back. CDXS has the team in place now for a buyout were blue chip companies plugs and plays the team and technology into their platform. Got to se the angles before they are played. Again this is a technology company stated by the CEO who only has multi billion exits on his resume.
Big announcement coming if you don't know their multiple Ligase contracts with some of the biggest companies in the space. And full enzymatic drug manufacturing this is ultimate RFK and and Tariff stock if you think about it. Making drugs clean purer higher yields and on US soil. Some people will make life changing wealth at these levels.
https://www.codexis.com/
Catalyst:
• Achieve pilot scale production with ECO Synthesis Innovation Lab
for GLP material
• Sign a GMP scale-up partnership
• Secure ECO Synthesis raw materials supply chain
• TIDES USA & Europe annual meetings
Demonstrate purity & yield equivalent or better than phosphoramidite chemistry
Highlight ECO Synthesis incorporation of additional modified nucleotides
Joint presentations with key siRNA innovators & CDMOs
Losers Sold to $ Smart Big announcements imminent.
BTW RFK will be a backer of Water based enzyme manufacturing platforms side stepping the nasty chemical manufacturing in place now where most the toxins come from China & India. The people who really understand the company and where they are going are just adding shares 450 Drugs in the pipeline including 55 Phase 2 & 3 Late stage trials.
• Convert pipeline of 7+ potential customers into revenue
generating contracts
$CDXS
TechandBio
1年前
CDXS Enzymatic RNA Manufacturing
Codexis provides a range of RNA manufacturing services using proprietary enzymatic technologies to enable nucleic acid therapeutics development. Leveraging the Enzyme-Catalyzed Oligonucleotide (ECO) SynthesisTM manufacturing platform, sequences with modified RNA bases and tissue-targeting moieties can be synthesized to maximize yield and purity, while adopting economically sound, scalable pathways. Our technology operates under aqueous conditions that are milder than the current solid phase oligonucleotide synthesis (SPOS) processes, thereby significantly reducing the complexity of impurities and the use of organic solvents during synthesis.
Codexis’ ECO Synthesis Innovation Lab will take a collaborative approach to design a project development plan that works for you. We can customize analytical methods, tailor final deliverable scales, and provide additional custom services to meet your needs. Additionally, Codexis enables technology transfer of our process to your chosen manufacturing site for scaling up and production under GMP.
It's coming!
TechandBio
1年前
7 deals are in the works so far what will be the next blue chip that partners with CDXS in 2025
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
https://www.codexis.com/investors/news-events/press-releases/detail/384/codexis-enters-exclusive-licensing-agreement-for-newly
Dilly has sold his last two companies for 1.9 Billion & 2.6 Billion CDXS will be his largest exit. This market and technology growth dwarfs anything he has ever been a part of.
1k metric ton to 30k Metric tons by 2030 time period for RNAI drugs market 3000% growth from today if they can capture 10-15% of that market which is what DIlly is forecasting your looking at company 50x the market cap of today.
Google Enzymatic RNAI drug manufacturing:
AI Overview
Learn more
Enzymatic RNAi drug manufacturing, specifically using Enzyme Catalyzed Oligonucleotide (ECO) Synthesis technology, offers a promising, scalable, and efficient approach to producing siRNA therapeutics, potentially revolutionizing the manufacturing of RNA-based drugs.
Here's a more detailed explanation:
What is Enzymatic RNAi Manufacturing?
Traditional chemical synthesis of siRNAs can be costly and time-consuming, limiting scalability.
Enzymatic synthesis, particularly using the ECO Synthesis platform, offers a potential solution by using enzymes to build RNA oligonucleotides (siRNAs).
This approach aims to address scalability and cost limitations, enabling the commercial-scale manufacture of RNAi therapeutics.
Codexis and the ECO Synthesis Platform:
Codexis is a company focused on developing and commercializing enzymatic technologies for biopharmaceutical applications.
Their ECO Synthesis platform is designed to enable the enzymatic synthesis of siRNAs and other RNA-based therapeutics.
Codexis has demonstrated the enzymatic synthesis of full-length sense strands of the oligonucleotide lumasiran and shorter sense strand fragments of givosiran, both commercially available siRNA therapeutics.
Benefits of Enzymatic Synthesis:
Scalability: Enzymatic processes can be scaled up more easily than traditional chemical synthesis.
Efficiency: Enzymatic synthesis can be more efficient and faster than chemical synthesis.
Cost-Effectiveness: Enzymatic synthesis can potentially reduce manufacturing costs.
Purity: Enzymatic pathways can lead to higher purity siRNA products.
Some people who invest at these levels will potentially see life changing wealth they have the team to execute and make it happen.
The Ceo see the company as a disruptive technology company and can plug and play this manufacturing with a wide array of drug modalities
OpalEye fund Casdin and Blackrock represent a third of the ownership $100.00+ price tag potential by 2030? Got to see the angles before they are played.
Check out the new March Biz presentation now up on their website.
$CDXS
TechandBio
1年前
This is one of the most undervalued stocks on the market. An aquas based drug manufacturing platform that will disrupt the chemical plants manufacturing business. This stock can see 100.00+ sooner than you can imagine. Think Catelent 2.0
Chart will see 10.00-20.00+in the coming months or sooner and looking for an all time break and blue sky breakout past the $42.00 mark.
This stock will create serious wealth for investors! The first time in history a company enzymatically made a drug CDXS synthetically made Novartis Leqvio® (inclisiran) 4 distinct ways Purer Cleaner and higher Yields at a fraction of the price of A "phosphorus chemical plant's
This is a next level technology play if you do your homework 1 metric ton to 30 metric tons growth from today to 2030 3000% growth CDXS looks to capture 15% of that Tam looking to make 1.5 Billion in revenue growing in the coming years. they have a revenue generating business today and have multiple big pharma contracts that are being finalized my guess Novartis and Alnylam for their Eco Synthesis partner CDMO partnership where they will be able to scale Kilo Size batches. Right now they are making thousands of dollars per gram of RNAI drugs.
They can plug and play this disruptive technology process to any modality of medicines! Think about that for a minute!
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
November 14, 2024 4:05 pm EST
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company’s rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform and establish Codexis’ position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.
Codexis Demonstrates First-ever Enzymatic Synthesis of Approved siRNA Therapeutic.
During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved RNAI therapeutic asset, inclisiran. Codexis enzymatically synthesized the full-length sense and antisense strands of the molecule, including the enzymatic incorporation of a tissue-targeting moiety to the sense strand. To date, this process has only been completed utilizing phosphoramidite chemistry, a process that involves the use of harsh chemical conditions and vast amounts of toxic organic solvents. By contrast, Codexis’ ECO Synthesis manufacturing platform operates under milder, aqueous conditions, that improves product quality and dramatically decreases chemical waste production.
In addition to this fully enzymatic route of synthesis, the Company demonstrated similar outcomes utilizing three routes of enzymatic ligation to produce the siRNA therapeutic asset, combining oligonucleotide fragments made by sequential enzymatic synthesis and traditional phosphoramidite chemistry. Key data from the presentation include:
Achieved incorporation efficiency of >98% during sequential enzymatic oligo synthesis
Successfully attached the tri-GalNAc tissue-targeting moiety by enzymatic ligation
Obtained full-length oligonucleotides of equal quality and yields, using ligation of short fragments made with enzymes or by traditional phosphoramidite chemistry
Now that Codexis has successfully achieved this unprecedented milestone, the Company will continue to optimize its process for robustness, scaled-up quantities and improved purity with the goal of providing customers with siRNA material of comparable or better quality to phosphoramidite chemistry
CEO Dilly has sold his last 2 companies for multi billions. I believe he will get 5-10 Billion for CDXS!
$CDXS
TechandBio
1年前
I hired a Private investigator he told me that he believes a buyout is being discussed if that happens I see 1.5 Billion price tag like the Roche PSTX deal that happened recently it's possible maybe Roche is one of companies discussing buyout! makes since with no news flow last two quarters things are going to get very interesting!
LASTY Opaleye Management Inc. FUND owns 3.99M shares of HROW Sep 30, 2024 11.20% of the company 142,682,393 Million they started buying HROW early in the single digits HROW went from $7.00-$60.00 low to high this year.
Opal Eye owns about 11% of CDXS after they have been accumulating shares this year they understand the landscape better than most!
Opaleye Management Inc. CDXS 8.77M Sep 30, 2024 10.78% 50,295,951
Opaleye Management's holdings in Codexis have significantly increased. The firm now owns 8,435,000 shares directly through Opaleye, L.P.
We’ve engineered the enzymes that have enabled some of the biggest pharmaceutical products ever developed, including Januvia (sitagliptin), Lipitor (atorvastatin) and Paxlovid (nirmatrelvir). Our work has been recognized with multiple Green Chemistry Challenge Awards from the American Chemical Society and we are known for our platform’s proven ability to revolutionize enzyme performance by increasing activity, specificity, and stability. Building upon this legacy, today we are focused on applying our deep expertise to the enzymatic manufacturing of small interference oligonucleotide (siRNA) therapeutics. 450-600 Drugs in these pipelines CDXS looks to capture 15% of this market.
I hope Dilly doesn't sell out to much upside here. I want 5-10 Billion over the next 24-36 months. 1.5 Billion in revenue projected in the coming years.
Significant CapEx Requirements
• Agilent invested $725M in facility expansion1 to produce
up to 1K kg of RNAi oligonucleotides per year
• $10B to $20B infrastructure investment required
to meet anticipated annual demand of ~30K kg by ~2030
Challenges with Phosphoramidite Chemistry
• Currently limited to single-digit kg batch sizes
• Bottlenecks for development-stage assets
• Requires large volumes of toxic & flammable
solvents
• Produces costly, harmful chemical waste
• Low purity output
• Significant capital investment for raw materials,
purification and waste disposal
Jefferies London Healthcare Conference ( must listen to this)
https://www.codexis.com/investors/news-events/ir-calendar/detail/12051/jefferies-london-healthcare-conference.
TIDES Europe - Process Development for Enzymatic Synthesis of RNAi Therapeutics
https://d1io3yog0oux5.cloudfront.net/_4244c8e9f072adc28a11c85c474ff11f/codexis/db/1161/12063/file/TIDES_Europe_-_Process_Development_for_Enzymatic_Synthesis_of_RNAi_Therapeutics.pdf
News on multiple fronts are due!
$CDXS
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
INV4
3月前
glenn1919
3月前
Monksdream
1年前
TrendTrade2016
1年前
メールアドレスで登録
